Sareum soars after colon cancer study

Shares in Sareum were soaring after the cancer drug discovery business announced positive results from a study into colon cancer. The study, which was conducted by the Institute of Cancer Research, founded that Sareum's Chk1 inhibitor, used alongside a gemcitabine, a chemotherapeutic, "demonstrates a greater than two-fold reduction in cancer growth rate compared to treatment with the same dose of gemcitabine without the Chk1 inhibitor."Sareum said that further studies showed that the Chk1 inhibitor used alone can "reduce cancer growth in models of AML (acute myeloid leukaemia) and neuroblastoma (a childhood cancer)."Sareum chief executive Tim Mitchell said: "These are exciting advances, demonstrating efficacy of our Chk1 compounds in several cancer models."Shares in the cancer drug efficiency modeller Physiomics are also sharply higher today. Last month Physiomics made three statements saying it new of no reasons for a spike in the company's share price, which came at the same time as a jump in Sareum's share price following Sareum's announcement of positive results from a study into leukaemia.Sareum and Physiomics last year signed an agreement that involves Physiomics supporting Sareum's cancer drug joint research program with the ICR and cancer discovery group Cancer Research Technology.